Palm Tocotrienols

Not the palm oil you used to know

 

1990’s

Successful extraction of tocotrienols from palm oil. Tocotrienols encapsulation into pharmaceutical dosage

1995

First US NIH (National Institute of health) funded study

2003

US patent granted for SupraBioTM delivery system

2007

US FDA approval for GRAS status

2013

First completed human clinical study on cell protection

2014

Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on Brain White Matter.

Read more

Recent research shows that palm tocotrienols help to protect brain cells and attenuate brain cells damages.

Tocotrienols were proven to reduce the progression of WMLs formation in the brain, hence is a promising ingredient in reducing a form of brain cells degeneration, the risk of Stroke & Dementia.

STROKE JOURNAL

A recent human clinical trial published in the American Heart Association’s journal, Stroke, reported that Tocovid SupraBio™ supplementation for two years at 200 mg twice daily slows down the development of white matter lesions (WMLs) in human brain. WMLs are closely related to vascular events of the brain and are indications of fragile brain vascular network, as well as an independent prognostic measure of future stroke risk and other cognitive health illness, dementia and Alzheimer’s disease.This study involved 121 participants, the largest human clinical study that is ever conducted for tocotrienols to date.